Confidential Joint Venture Materials
White Paper
Natural killer cell therapy for cancer: human evidence, manufacturing science, regulatory analysis, and investor diligence.
Executive Scientific Assessment
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system. Their antitumor relevance is supported by decades of basic immunology, observational human data linking intratumoral NK-cell infiltration with prognosis, and a growing body of adoptive-cell clinical research. The field now spans unmodified peripheral-blood NK cells, haploidentical NK cells, cytokine-induced memory-like NK cells, cord-blood NK cells, NK-92-derived products, induced-pluripotent-stem-cell-derived NK cells, and genetically engineered CAR-NK platforms.
The strongest human evidence remains in hematologic malignancies. A landmark 2005 study showed in-vivo expansion of haploidentical NK cells after intensive lymphodepletion and complete hematologic remissions in 5 of 19 poor-prognosis AML patients. A 2016 first-in-human memory-like NK study reported clinical responses in five of nine evaluable AML patients, including four complete remissions. In 2020, a New England Journal of Medicine study of cord-blood-derived CD19 CAR-NK cells established a major proof of concept for engineered allogeneic NK therapy in CD19-positive lymphoid malignancies.
Solid-tumor evidence is materially less mature. A 2024 systematic review/meta-analysis identified 31 trials involving 600 patients across multiple solid cancers, but heterogeneity, combination regimens, small cohorts, and early-phase designs limit causal inference. A 2026 clinical-trial landscape analysis identified 287 NK-based trials globally, most planned or early phase. The scientifically supportable investor thesis is therefore not that NK cells are a proven general cancer cure, but that NK-cell therapy is a legitimate and rapidly developing immuno-oncology platform with a comparatively attractive allogeneic manufacturing and safety rationale.
For the contemplated outsourced-processing/allogeneic clinic model, the decisive diligence issue is product-specific. Published evidence from one NK platform cannot automatically validate a different donor source, expansion method, cryopreservation process, dose, schedule, combination regimen, or cancer indication. The business model is scientifically stronger if it uses a characterized GMP-grade product, defined release criteria, physician-led eligibility, pharmacovigilance, prospective outcomes capture, and indication-specific evidence rather than a generic 'NK cells treat cancer' proposition.
Evidence Grading Used in This White Paper
| Tier | Meaning | Investor Interpretation |
|---|---|---|
| A | Replicated/established biology or mature clinical evidence | May support strong factual statements, subject to product/indication limits. |
| B | Human clinical signal from prospective trials or systematic evidence | Supports a credible development thesis, not a general efficacy claim. |
| C | Early-phase, small-cohort, nonrandomized, combination, or heterogeneous evidence | Promising; requires explicit qualification. |
| D | Preclinical/mechanistic rationale | Supports hypothesis and development strategy, not patient-outcome claims. |
Contents
1. NK-Cell Biology and Cancer Immunosurveillance
2. Mechanisms of Tumor Recognition and Killing
3. Sources and Classes of Therapeutic NK Cells
4. Human Clinical Evidence: AML and Myeloid Malignancies
5. Human Clinical Evidence: Lymphoid Malignancies
6. Human Clinical Evidence: Solid Tumors
7. CAR-NK and Engineered NK Platforms
8. Tumor Microenvironment and Resistance
9. Comparison with CAR-T, TIL, Checkpoint Inhibitors and Other Immunotherapies
10. Manufacturing Science and CMC
11. Donor Selection, Collection and Starting Material
12. Expansion, Activation, Cryopreservation and Release Testing
13. Clinical Logistics and Chain of Identity/Custody
14. Competitive Biotechnology Landscape
15. Patent and Intellectual-Property Landscape
16. United States Regulatory Framework
17. Mexico Regulatory Framework
18. Japan and South Korea Regulatory Frameworks
19. Other Jurisdictions and Cross-Border Considerations
20. Scientific Assessment of the Outsourced-Processing Clinic Model
21. Risk Register and Joint Venture Partner Diligence Questions
22. Conclusions
Appendix A. Major Published Human Studies
Appendix B. Modality Comparison
Appendix C. Manufacturing and Release-Testing Checklist
Appendix D. Regulatory Diligence Checklist
Appendix E. Annotated Bibliography and Source Links
1. NK-Cell Biology and Cancer Immunosurveillance
Innate immune role
NK cells provide rapid cytotoxic responses without the clonal priming required for conventional adaptive T-cell responses. Their phenotype is commonly defined by CD56 expression and absence of CD3, with functional diversity across CD56bright and CD56dim populations. For oncology, the central concept is integration of activating and inhibitory signals rather than recognition of one mandatory tumor antigen.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Missing-self recognition
Many malignant cells downregulate HLA class I as an immune-evasion mechanism against cytotoxic T cells. NK cells can exploit this change because inhibitory KIR and NKG2A signaling is reduced when appropriate self-HLA ligands are absent or altered. This ‘missing-self’ framework is one reason allogeneic NK cells can exhibit antitumor alloreactivity.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Stress-ligand recognition
Activating receptors including NKG2D and natural cytotoxicity receptors detect stress-associated ligands that can be increased on transformed cells. The balance of activating and inhibitory receptor engagement determines whether the NK cell forms a cytotoxic synapse and executes killing.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Clinical correlative evidence
A systematic review/meta-analysis of 53 studies found that NK-cell infiltration in solid tumors was associated with improved overall survival, supporting the biological relevance of endogenous NK surveillance while not proving that adoptive NK infusion produces the same benefit.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
2. Mechanisms of Tumor Recognition and Killing
Perforin and granzyme
After target recognition, cytotoxic granules polarize toward the immune synapse. Perforin facilitates granzyme entry and apoptotic death. This mechanism is antigen-independent in the sense that it does not require a rearranged antigen-specific T-cell receptor.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Death-receptor pathways
NK cells can engage death receptors through Fas ligand and TRAIL pathways. These mechanisms complement granule exocytosis and may vary by tumor phenotype.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
ADCC
CD16 (FcγRIIIa) enables NK cells to recognize antibody-coated targets. This creates a strong rationale for combining NK products with tumor-targeting monoclonal antibodies such as rituximab in CD20-positive disease.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Cytokine effects
NK-derived IFN-γ and other cytokines shape adaptive and innate immune responses. Cytokine support can enhance expansion and persistence but also changes the safety and regulatory profile of a treatment regimen.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
3. Sources and Classes of Therapeutic NK Cells
Peripheral-blood NK
Healthy-donor peripheral blood is a clinically intuitive source. Leukapheresis provides larger mononuclear-cell yields than ordinary whole-blood collection and is generally more compatible with scalable manufacturing.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Cord-blood NK
Cord blood provides bankable allogeneic starting material and has been used for CAR-NK development. The 2020 NEJM CD19 CAR-NK study is the best-known clinical proof of concept.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
NK-92 and cell lines
NK-92 offers manufacturing uniformity and expansion advantages but is biologically and regulatorily distinct from primary donor NK cells and typically requires irradiation before administration because it is an immortalized cell line.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
iPSC-derived NK
iPSC-derived NK platforms aim for clonally defined, engineerable, highly scalable off-the-shelf products. Their economics and reproducibility are attractive, but evidence must be evaluated product by product.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Memory-like NK
Brief IL-12/IL-15/IL-18 preactivation can generate cytokine-induced memory-like properties. Human AML data demonstrate in-vivo expansion and antileukemia responses, making this a clinically important branch of the field.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
4. Human Clinical Evidence: AML and Myeloid Malignancies
Miller 2005
The University of Minnesota study established that haploidentical NK cells could persist and expand after high-intensity cyclophosphamide/fludarabine lymphodepletion. Five of 19 poor-prognosis AML patients achieved complete hematologic remission. The study was small and nonrandomized, but it remains foundational.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Romee 2016
Cytokine-induced memory-like NK cells were tested in a first-in-human phase I setting. Five of nine evaluable AML patients responded, including four complete remissions. The trial supports the concept that ex-vivo activation state can materially alter therapeutic behavior.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
KIR mismatch and alloreactivity
Clinical studies in older/high-risk AML have demonstrated feasibility of KIR-ligand-mismatched haploidentical NK infusion with limited NK-related toxicity. Response heterogeneity emphasizes the importance of disease burden, conditioning, persistence and donor biology.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Interpretation
AML provides the strongest historical proof that unmodified or activated allogeneic NK cells can produce clinically meaningful antileukemia effects. It does not establish efficacy of a different outpatient product in solid tumors.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
5. Human Clinical Evidence: Lymphoid Malignancies
CD19 CAR-NK
The 2020 NEJM report of cord-blood-derived CD19 CAR-NK cells demonstrated rapid responses in CD19-positive lymphoid tumors and a favorable early safety profile. It materially strengthened the off-the-shelf NK thesis.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Antibody combinations
NK-cell ADCC provides a mechanistic basis for pairing NK therapy with anti-CD20 antibodies. Current programs continue to investigate chemotherapy-free or reduced-lymphodepletion combinations, but company-reported interim results require confirmation in peer-reviewed mature datasets.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Safety proposition
Across multiple NK platforms, severe CRS, ICANS and GVHD have generally appeared less prominent than in autologous CAR-T experience. Cross-trial comparisons are imperfect because populations, conditioning, constructs, cell doses and toxicity ascertainment differ.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
6. Human Clinical Evidence: Solid Tumors
Systematic evidence
A 2024 systematic review/meta-analysis included 31 trials and 600 patients with cancers including NSCLC, hepatocellular, breast and ovarian malignancies. The aggregate signal was encouraging, but studies were heterogeneous and frequently used NK cells with other therapies.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
NSCLC
A 2025 systematic review/meta-analysis of nine trials involving 324 advanced NSCLC patients found exploratory signals in disease control and one-year survival, with substantial heterogeneity and limitations. These data support continued investigation rather than a definitive efficacy claim.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Mixed solid tumors
A phase I study of expanded allogeneic healthy-donor NK cells in malignant lymphoma or advanced solid tumors established feasibility of repetitive unrelated-donor administration. Such studies are important safety precedents but are not equivalent to randomized efficacy evidence.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Investor interpretation
The solid-tumor investment case rests on biological plausibility, favorable safety experience, improving manufacturing, combination strategies and a large clinical-development pipeline. The efficacy case remains indication- and regimen-specific.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
7. CAR-NK and Engineered NK Platforms
Why engineer NK cells
CARs can add antigen-directed recognition while preserving innate NK killing. Engineering may also address persistence, trafficking, checkpoint inhibition and cytokine support.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Potential advantages
Allogeneic sourcing, reduced GVHD propensity and potentially lower rates of severe CRS/ICANS are repeatedly cited advantages. Off-the-shelf manufacturing could reduce vein-to-vein delay compared with autologous CAR-T.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Limitations
Persistence may be shorter than desired; transduction/editing can be technically difficult; cryopreservation can reduce function; antigen heterogeneity and solid-tumor trafficking remain major problems.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
State of field
A 2026 review describes CAR-NK solid-tumor translation as promising but nascent, with hostile TME, infiltration and persistence as central barriers.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
8. Tumor Microenvironment and Resistance
Hypoxia
Hypoxia changes tumor and immune-cell metabolism, stabilizes HIF pathways and can impair NK cytotoxicity. It is a major reason systemic infusion does not guarantee effective tumor-site activity.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
TGF-beta
TGF-β suppresses NK activation, receptor expression, metabolism and cytotoxicity. Engineering or combination approaches designed to resist TGF-β are therefore scientifically rational.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Physical exclusion
Dense extracellular matrix, abnormal vasculature and cancer-associated fibroblasts can impede NK trafficking and infiltration.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Metabolic suppression
Acidosis, adenosine, nutrient depletion and lactate can reduce NK-cell fitness. These factors help explain why hematologic success does not automatically translate to solid tumors.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Antigen and ligand escape
Tumors can shed or downregulate activating ligands and alter HLA expression. Engineered multispecific recognition and antibody combinations are being explored to reduce escape.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
9. Comparison with CAR-T, TIL, Checkpoint Inhibitors and Other Immunotherapies
CAR-T
CAR-T has demonstrated transformative efficacy in several hematologic cancers and has multiple FDA approvals. NK platforms seek improved allogeneic availability and tolerability, but currently lack the same depth of approved oncology efficacy evidence.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
TIL
TIL therapy exploits naturally tumor-reactive lymphocytes harvested from tumor tissue. It can be powerful in selected solid tumors but requires tumor procurement, individualized manufacturing and intensive clinical support.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Checkpoint blockade
Checkpoint inhibitors have broad standard-of-care roles across solid tumors. They release inhibitory brakes on endogenous immunity rather than supplying a new cytotoxic-cell population. NK combinations are biologically plausible but must be proven clinically.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Monoclonal antibodies
Antibodies can directly block signaling or recruit immune effectors. Because NK cells mediate ADCC through CD16, antibody-NK combinations are particularly rational.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Dendritic-cell approaches
Dendritic-cell vaccines seek antigen presentation and adaptive immune priming. Their mechanism and manufacturing differ fundamentally from direct NK cytotoxic therapy.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Cytokines
IL-2 and IL-15 can expand/activate NK cells but have systemic effects and toxicity considerations. Cytokine engineering and localized support are active development areas.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Stem-cell-derived immune products
HSC- or iPSC-derived immune-cell platforms are manufacturing sources rather than evidence that undifferentiated stem cells themselves treat cancer. Investor materials should keep those concepts distinct.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
10. Manufacturing Science and CMC
Manufacturing defines the product
For living-cell therapies, process is inseparable from product. Donor source, isolation, activation, expansion, feeder system, media, cytokines, culture duration, washing, formulation, cryopreservation and thawing can alter phenotype and potency.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Closed GMP processing
A commercially credible platform should migrate toward closed or functionally closed GMP-compatible operations, qualified reagents, validated equipment, environmental monitoring and traceable electronic batch records.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Comparability
Any move from outsourced CMO production to an owned laboratory requires comparability work. A clinically used dose manufactured under one process cannot be assumed equivalent after process changes.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Scale economics
The commercial objective is sufficient doses per donor/collection while maintaining potency, viability and phenotype. Cryobanking can decouple manufacturing from administration, but post-thaw potency is a critical variable.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
11. Donor Selection, Collection and Starting Material
Donor eligibility
Donor screening should address infectious disease, medical history, collection suitability and jurisdiction-specific donor-eligibility requirements. Product-specific KIR/HLA characteristics may also matter.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Leukapheresis versus whole blood
Leukapheresis generally yields far more mononuclear cells and is the preferred starting material for scalable primary-cell manufacturing. Whole blood or buffy coat may reduce procurement cost but can constrain yield and batch scale.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Chain of identity
Even for allogeneic products, donor/batch identity and recipient allocation require robust chain-of-identity and chain-of-custody systems.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Blood-bank sourcing
A licensed blood bank may be a source of starting material, but blood-bank status alone does not establish that subsequent expanded NK cells satisfy medicinal-product/cell-therapy manufacturing requirements.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
12. Expansion, Activation, Cryopreservation and Release Testing
Expansion technologies
Clinical and experimental platforms use cytokines, feeder cells, membrane-bound cytokines, antibodies, bioreactors and combinations thereof. Expansion fold alone is not a sufficient quality metric.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Cryopreservation
Cryopreservation enables inventory and distribution but can impair viability, receptor expression, metabolism and cytotoxicity. Post-thaw recovery and potency should therefore be release or characterization priorities.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Core release attributes
Typical diligence categories include identity, purity, viability, sterility, mycoplasma, endotoxin, residual T cells, dose/cell count and a validated or qualified potency assay.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Potency
A defensible potency assay should reflect the intended biological activity and be sufficiently reproducible for lot release and stability studies. Cytotoxicity against a relevant target, degranulation or other functional readouts may be used depending on product design.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
13. Clinical Logistics and Chain of Identity/Custody
Cold chain
Cryopreserved allogeneic product requires qualified shipping containers, temperature monitoring, receiving controls, controlled storage and documented thaw procedures.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Administration
Administration should occur under physician responsibility with product-specific premedication, monitoring and emergency-response capability. Requirements depend on conditioning, cytokine support and product risk.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Pharmacovigilance
A serious commercial program should capture infusion reactions, infections, cytopenias, CRS, neurologic events, hospitalization, disease response and longer-term outcomes.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Data architecture
Prospective structured data are strategically valuable. They support quality improvement, physician oversight, payer/investor diligence and potentially future formal clinical development.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
14. Competitive Biotechnology Landscape
Nkarta
Nkarta develops engineered allogeneic NK products. By 2026 its public focus had shifted substantially toward B-cell-mediated autoimmune disease, illustrating both platform versatility and the commercial difficulty of oncology cell therapy.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Artiva
Artiva's AlloNK is a non-genetically modified, cryopreserved NK product being studied with B-cell-targeted monoclonal antibodies. Its platform is directly relevant to the commercial concept of banked allogeneic NK cells.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
ImmunityBio
ImmunityBio is developing NK-based products including CAR-NK and memory cytokine-enhanced NK approaches and has reported manufacturing scale-up and cryobanking work.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Century Therapeutics
Century has developed iPSC-derived immune-cell platforms including iNK technology, although pipeline priorities evolve. The company illustrates the engineered, clonally scalable end of the NK manufacturing spectrum.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Competitive lesson
The field is technically credible but commercially dynamic. Pipeline reprioritizations, partnerships and discontinued programs are as important to diligence as positive press releases.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
15. Patent and Intellectual-Property Landscape
Layered IP
Relevant patent estates commonly include cell composition, CAR constructs, gene edits, cytokine support, feeder/expansion methods, cryopreservation, manufacturing processes and methods of treatment.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Freedom to operate
A clinic buying a finished product faces a different FTO profile from a company manufacturing or engineering NK cells. Vertical integration increases potential exposure to process and platform patents.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Trade secrets
Manufacturing know-how, media composition, timing, cell handling and release analytics may be protected as trade secrets even where patent claims are narrow.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Diligence strategy
Before building an owned lab, counsel should conduct claim-level searches around the exact expansion process, feeder system, cytokine configuration, engineering, cryopreservation and intended therapeutic combinations.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
16. United States Regulatory Framework
FDA jurisdiction
FDA explicitly includes natural killer cells within oncology cell and gene therapy. Manipulated/expanded allogeneic NK products intended to treat cancer would ordinarily be evaluated as biological products requiring an IND for clinical investigation and a BLA for commercial marketing in the United States.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
361 HCT/P distinction
The lower-burden 361 HCT/P pathway is generally not a realistic basis for ex-vivo expanded allogeneic NK cells intended to treat cancer because manipulation and non-homologous-use issues are central.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Manufacturing
U.S. clinical development requires CMC information sufficient to establish identity, purity, potency and safety, with increasing expectations as development advances.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Marketing
Even where services occur outside the United States, U.S.-directed advertising, investor statements, physician communications and patient acquisition should avoid implying FDA approval or established efficacy that does not exist.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
17. Mexico Regulatory Framework
Core issue
Mexico is potentially attractive for a cross-border clinic, but the legal path must be confirmed for the exact NK product and workflow. The fact that a physician may practice medicine or that a clinic holds a health license does not by itself resolve authorization for manufacture, importation, storage or administration of an expanded allogeneic cellular product.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
COFEPRIS diligence
The project should obtain written Mexican regulatory analysis addressing product classification, establishment licenses, import permits, blood/tissue sourcing, processing authorization, clinical-research requirements, advertising, informed consent, pharmacovigilance, storage and transport.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Outsourced CMO
Using a third-party processor can reduce capital needs but does not eliminate sponsor/clinic responsibility. Contracts should allocate GMP status, batch release, deviations, recalls, sterility failures, adverse-event reporting, transport excursions and indemnification.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Investor gate
No investor deck should state that the Tijuana model is 'COFEPRIS approved' until the exact clinic, product, manufacturer and authorization pathway are documented.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
18. Japan and South Korea Regulatory Frameworks
Japan
Japan operates dual frameworks under the Act on the Safety of Regenerative Medicine and the PMD Act. The ASRM reaches regenerative medicine provided in medical practice as well as research, while the PMD Act governs regenerative medical products.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
South Korea
South Korea has been a major center of NK clinical research and commercial development. Regulatory analysis should distinguish clinical research, advanced regenerative medicine, manufacturing and product approval pathways.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Comparative lesson
Jurisdictions that facilitate regenerative medicine still impose product, facility, review, consent and safety obligations. 'Medical practice' is not synonymous with unregulated cell therapy.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
19. Other Jurisdictions and Cross-Border Considerations
Jurisdiction selection
Potential jurisdictions should be compared on product classification, clinical evidence requirements, importation, manufacturing licensing, physician scope, advertising, pharmacovigilance, malpractice exposure and enforceability.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Medical tourism
Cross-border patient acquisition creates heightened informed-consent and continuity-of-care issues. Patients should understand investigational status, alternatives, expected costs, follow-up and emergency arrangements.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Data protection
Cancer records and genomic/immune data may implicate local privacy rules and cross-border transfer restrictions.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
20. Scientific Assessment of the Outsourced-Processing Clinic Model
Scientific strengths
The model reduces initial capex, allows reliance on specialized manufacturing, and can use cryopreserved inventory rather than patient-specific manufacturing. It aligns with the broader industry's off-the-shelf objective.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Scientific weaknesses
The clinic does not control manufacturing variables and may have limited ability to validate potency, stability or comparability. If the CMO's product lacks strong indication-specific human evidence, the clinic cannot cure that evidentiary gap through branding.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Best defensible positioning
The strongest model is an oncology-adjacent investigational cellular-therapy program integrated with conventional oncology, not a replacement for surgery, chemotherapy, radiation, targeted therapy or approved immunotherapy.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Clinical governance
A medical advisory board, indication-specific eligibility criteria, independent pathology confirmation, baseline staging, treating-oncologist coordination and standardized response assessment materially improve credibility.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Data strategy
Prospective registry-style data collection should be designed before first commercial treatment. It should capture product lot, dose, viability, concomitant therapy, disease status, RECIST or disease-specific response, survival and adverse events.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
Vertical integration trigger
An owned processing lab becomes rational when treatment volume, CMO margin, supply risk, IP access and regulatory pathway justify the fixed cost and validation burden. It should be a second-stage decision, not an assumption.
Due-diligence implication. Any investor claim should be tied to the exact cell source, manufacturing process, indication and clinical context. Cross-platform extrapolation should be identified as scientific rationale rather than direct clinical proof.
21. Risk Register and Joint Venture Partner Diligence Questions
Scientific risk
Will the selected product demonstrate meaningful activity in the cancers actually targeted by the clinic?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Regulatory risk
Is manufacture/import/storage/administration lawful for the exact product and indication?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
CMC risk
Are potency, sterility, viability and lot consistency independently documented?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Clinical risk
Can the clinic identify, monitor and manage complications and coordinate with conventional oncologists?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Commercial risk
Will patients pay out of pocket for an investigational adjunct when evidence is heterogeneous?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Reputation risk
Overstated cure claims could damage the enterprise, physician relationships and future regulatory options.
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Supply risk
Can the CMO provide predictable batches, validated shipping and recall support?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
IP risk
Does eventual in-house expansion infringe third-party process or platform rights?
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
22. Conclusions
Bottom line
NK-cell oncology is scientifically legitimate and clinically active. Human evidence is strongest in hematologic malignancies; solid-tumor evidence is promising but heterogeneous and generally early. The platform's commercial appeal derives from innate cytotoxicity, allogeneic potential, repeat dosing and off-the-shelf manufacturing.
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Business-plan conclusion
The proposed clinic can be presented credibly to investors if the business plan is explicit that the therapy is investigational, product-specific, adjunctive, physician-directed and subject to local authorization. The enterprise becomes materially more defensible when it couples a qualified product with rigorous outcomes collection and avoids extrapolating CAR-NK or AML results to unrelated unmodified NK protocols.
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Investment thesis
The investment case should therefore be framed as building an evidence-generating, quality-controlled access platform around a rapidly developing immunotherapy modality—not monetizing a claim that NK cells are already proven to cure solid tumors.
Due-diligence implication. This issue should be converted into a documented diligence item with an owner, source document and go/no-go criterion before capital is committed.
Appendix A. Major Published Human Studies
| Study | Cancer | Product/source | Design | N | Regimen | Key finding | Limitations |
|---|---|---|---|---|---|---|---|
| Miller et al., 2005 | AML and other cancers | Haploidentical PB-NK | Phase I/feasibility | 19 poor-prognosis AML in intensive cohort | Hi-Cy/Flu; IL-2 | 5/19 AML complete hematologic remissions; donor NK expansion linked to intensive lymphodepletion | Small, nonrandomized; conditioning confounds efficacy |
| Romee et al., 2016 | AML | Cytokine-induced memory-like allogeneic NK | Phase I | 9 evaluable | IL-12/15/18 preactivation | 5/9 clinical responses, including 4 CR | Very small cohort; early phase |
| Liu et al., 2020 | CD19+ lymphoid tumors | Cord-blood CD19 CAR-NK | Phase I/II | 11 treated in initial report | Lymphodepletion; engineered IL-15 CAR-NK | Major proof of concept for rapid responses and favorable early safety | Small, single-center; engineered product not generalizable to unmodified NK |
| Yang et al., 2016 | Lymphoma / advanced solid tumors | Expanded unrelated healthy-donor NK (MG4101) | Phase I | 20 | Repeated allogeneic infusions | Feasibility and safety precedent; signals of activity | Heterogeneous cancers; early phase |
| Curti et al., 2011 | High-risk AML | KIR-ligand mismatched haploidentical NK | Clinical study | 13 | Flu/Cy; IL-2 | Feasible; responses in some active/molecular relapse patients; no NK-related GVHD reported | Small, heterogeneous disease status |
| Park et al., 2024 systematic review | Multiple solid tumors | Unmodified NK therapies | Systematic review/meta-analysis | 31 trials / 600 patients | Varied; often combinations | Aggregate promising ORR/safety signals | Marked heterogeneity; combination confounding; publication bias possible |
| 2025 NSCLC meta-analysis | Advanced NSCLC | NK therapy, varied | Systematic review/meta-analysis | 9 trials / 324 patients | 1-4×10^9 range; 2-3 cycles in included studies | Exploratory disease-control and survival signals; similar AE rates | Heterogeneity; bias; incomplete reporting |
Appendix B. Modality Comparison
| Modality | Personalized? | Approved oncology precedent | Major strength | Major limitation | Typical toxicity issue | NK-business relevance |
|---|---|---|---|---|---|---|
| Unmodified allogeneic NK | No / donor-batch | No U.S. cancer approval specific to NK product | Off-the-shelf potential; innate killing; ADCC | Persistence and solid-tumor efficacy | Infusion reactions, cytopenias/conditioning effects | Core contemplated model |
| CAR-NK | Potentially off-the-shelf | Investigational | Antigen targeting plus innate killing | Engineering, persistence, antigen escape | Early data suggest manageable CRS/GVHD profile | Validates platform direction, not identical product |
| CAR-T | Usually autologous; some allogeneic development | Multiple approvals | Deep responses in selected hematologic cancers | Cost, logistics, CRS/ICANS, limited solid-tumor success | CRS, ICANS, cytopenias | Benchmark competitor |
| TIL | Autologous | Approved precedent in melanoma | Polyclonal tumor recognition | Complex individualized manufacturing | Lymphodepletion/IL-2 toxicity | Solid-tumor comparator |
| Checkpoint inhibitors | Off-the-shelf drug | Many approvals | Broad standard-of-care footprint | Only subsets respond; immune-related AEs | Autoimmune/immune-related toxicity | Potential combination/standard-care context |
| Monoclonal antibodies | Off-the-shelf drug | Many approvals | Target specificity; ADCC | Antigen dependence/resistance | Infusion and target-specific effects | Strong mechanistic combination partner |
Appendix C. Manufacturing and Release-Testing Checklist
Appendix D. Regulatory Diligence Checklist
Appendix E. Annotated Bibliography and Source Links
Miller JS et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005. Source
Foundational haploidentical NK study; in-vivo expansion and AML remissions.
Romee R et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016. Source
First-in-human memory-like NK evidence in AML.
Liu E et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020. Source
Landmark cord-blood CAR-NK clinical proof of concept.
Yang Y et al. Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Source
Repeated unrelated-donor expanded NK feasibility/safety.
Curti A et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells... AML. Source
KIR-mismatch clinical feasibility and response data.
Park et al. Efficacy and safety of natural killer cell therapy in patients with solid tumors: systematic review and meta-analysis. Source
31 trials / 600 patients; useful aggregate solid-tumor evidence with heterogeneity caveats.
Clinical trial landscape and translational prospects of NK-cell-based immunotherapy. JITC. 2026. Source
Analysis of 287 NK clinical trials; useful global pipeline context.
NK cell infiltration is associated with improved overall survival in solid cancers: systematic review and meta-analysis. Source
Human tumor-correlative evidence supporting NK immunosurveillance.
Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions. 2026. Source
Current review of CAR-NK solid-tumor barriers and engineering strategies.
The critical role of the tumor microenvironment in shaping NK-cell-mediated anti-tumor immunity. Source
Foundational TME review.
TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy. 2026. Source
Current review of a central NK-suppressive pathway.
Tumor hypoxia shapes natural killer cell anticancer activities. 2025. Source
Mechanistic review of hypoxia-mediated NK dysfunction.
Successful expansion and cryopreservation of human NK-92 for clinical manufacturing. Source
Manufacturing/cryopreservation process evidence.
FDA Oncology Cell and Gene Therapy program. Source
FDA expressly identifies NK cells within oncology cell/gene therapy.
PMDA: Regenerative Medical Products regulatory framework. Source
Official Japan overview of ASRM and PMD Act dual framework.
Nkarta pipeline / corporate materials. Source
Current engineered NK platform context; verify pipeline dates before investor use.
Artiva Biotherapeutics corporate overview. Source
Current AlloNK platform and program context.
Century Therapeutics pipeline. Source
iPSC-derived immune-cell platform context.
ImmunityBio NK manufacturing update, March 2026. Source
Company-reported scale-up/cryobanking information; treat as issuer disclosure, not peer-reviewed proof.
Evidence Dossier: Acute myeloid leukemia
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Non-Hodgkin lymphoma / CLL
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Multiple myeloma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Non-small cell lung cancer
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Hepatocellular carcinoma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Breast cancer
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Ovarian cancer
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Colorectal cancer
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Gastric cancer
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Pancreatic cancer
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Glioblastoma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Renal cell carcinoma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Melanoma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Sarcoma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Evidence Dossier: Neuroblastoma
Diligence purpose. This dossier is a structured framework for evaluating whether a specific NK product and regimen can be responsibly positioned for this indication. It should be populated only with product-specific human evidence before the indication is marketed.
Biological rationale
Assess tumor expression of activating/inhibitory ligands, susceptibility to NK cytotoxicity, relevance of ADCC, and known mechanisms of NK exclusion or suppression.
Human evidence
Separate unmodified NK, activated/memory-like NK, CAR-NK and combination studies. Record prospective versus retrospective design, sample size, line of therapy and comparator.
Dose and schedule
Record viable cell dose, fixed versus weight-based dosing, number and spacing of infusions, lymphodepletion, cytokine support and concomitant anticancer therapy.
Efficacy endpoints
Capture ORR, CR, PR, stable disease, duration of response, PFS, OS and validated disease-specific endpoints. Do not substitute anecdotal tumor regression for trial-level efficacy.
Safety
Capture infusion reactions, fever, infection, cytopenias, CRS, neurotoxicity, GVHD, hospitalization and treatment-related mortality.
Transferability to clinic model
Determine whether the proposed CMO product is materially comparable in source, phenotype, manufacturing, potency, cryopreservation, dose and clinical context to the cited evidence.
Go/no-go standard
Do not designate an indication as evidence-supported for commercial outreach until medical and regulatory reviewers sign off on the exact claims and supporting studies.
Clinical Evidence Worksheet: Haploidentical NK in AML
Foundational clinical programs establish feasibility, in-vivo expansion and antileukemia activity. For diligence, conditioning intensity, donor persistence, disease burden and cytokine support must be treated as part of the regimen rather than incidental variables.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: Cytokine-Induced Memory-Like NK
IL-12/IL-15/IL-18 preactivation can create enhanced recall-like functional responses. Early AML clinical evidence is important but should not be generalized to conventionally expanded NK products.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: Cord-Blood CAR-NK
Cord-blood CAR-NK provides major proof of concept for banked allogeneic engineered NK therapy. Its CAR construct, IL-15 support and manufacturing distinguish it from unmodified donor NK.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: Unrelated Donor Expanded NK
Repeated healthy-donor NK infusion studies support feasibility. Product-specific expansion methods, KIR phenotype, dose, concomitant therapy and cryopreservation determine transferability.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK plus Rituximab
The combination is mechanistically compelling because CD16-mediated ADCC can recruit NK killing to antibody-coated CD20-positive cells. Clinical claims nevertheless require regimen-specific evidence.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK plus Checkpoint Blockade
Checkpoint combinations seek to reverse inhibitory signaling and improve endogenous/adoptive immune activity. Evidence remains product- and indication-specific.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK plus IL-15
IL-15 can promote NK proliferation and survival without some of IL-2's regulatory-T-cell effects, but systemic cytokine exposure introduces independent pharmacology and safety considerations.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK in Hepatocellular Carcinoma
Published aggregate analyses report encouraging response signals, often in combination with local or systemic therapy. Combination confounding prevents attribution of benefit to NK cells alone.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK in Ovarian Cancer
Ovarian cancer is biologically relevant to NK investigation, but trafficking, ascites-associated immunosuppression and TME effects remain important barriers.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK in Breast Cancer
Antibody-dependent cytotoxicity creates a rationale for combinations in antibody-targetable breast cancers. Product-specific clinical validation remains necessary.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK in Pancreatic Cancer
Pancreatic cancer presents an especially dense, immunosuppressive stroma. A mechanistic rationale does not overcome the absence of mature efficacy evidence.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK in Glioblastoma
Brain-tumor trafficking, local immune suppression and antigen heterogeneity create formidable translational barriers. Engineered and local-delivery strategies remain investigational.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Evidence Worksheet: NK in Melanoma
Melanoma is immunogenic and has established checkpoint/TIL treatment paradigms. NK strategies should be compared against these standards rather than evaluated in isolation.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Leukapheresis
Leukapheresis can provide high mononuclear-cell yields and supports scalable donor-derived manufacturing. Collection center qualification, donor testing, transport and hold times should be specified contractually.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Buffy Coat / Whole Blood
Lower-cost starting material may be feasible for some processes but generally constrains starting NK-cell numbers and batch scale. The economics must include expansion time, failure rate and final dose yield.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Feeder-Based Expansion
Feeder systems can achieve large expansion but introduce additional raw-material, clearance, residual-cell and regulatory controls. The exact feeder design can also be IP-sensitive.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Feeder-Free Expansion
Feeder-free processes may simplify CMC and reduce residual-cell concerns, but yield, phenotype and potency must be compared directly with the intended clinical specification.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Cryopreservation
Cryobanking is central to an off-the-shelf model. Stability studies should define storage duration, shipping limits, thaw recovery, viability, phenotype and potency through the intended administration window.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Potency Assays
Potency is a critical quality attribute. A clinic should not rely solely on viability and cell count; functional release/characterization should reflect tumor-cell killing or another validated mechanism.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: Sterility and Microbial Control
Cell products have limited shelf life, making sterility strategy operationally difficult. Rapid methods, environmental controls, quarantine/release rules and recall procedures must be aligned.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Manufacturing Dossier: CMO Qualification
CMO diligence should cover licenses, inspection history, quality systems, deviations, CAPA, batch failure, release authority, subcontractors, business continuity and insurance.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Operations Dossier: Patient Eligibility
Eligibility criteria should be indication-specific and medically governed. They should define performance status, organ function, infection, disease confirmation, prior therapy and contraindications.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Operations Dossier: Response Assessment
Use standardized oncology response criteria where applicable and prespecify imaging intervals. Anecdotal improvement and biomarker changes should not be substituted for objective tumor response.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Operations Dossier: Adverse Event Management
The clinic requires protocols for fever, infusion reaction, infection, cytopenia, CRS-like syndromes, neurologic symptoms and emergency transfer, even if severe toxicity is expected to be uncommon.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Clinical Operations Dossier: Conventional Oncology Coordination
The strongest adjunct model coordinates with the patient's oncologist and does not encourage abandonment of established treatment. Concomitant therapy must be captured because it affects both safety and efficacy interpretation.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Regulatory Dossier: Mexico Product Classification
Local counsel should classify the exact expanded allogeneic NK product and map every authorization implicated by manufacture, import, storage and administration. General regenerative-medicine descriptions are insufficient.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Regulatory Dossier: Mexico Clinical Establishment
Clinic licensing, responsible physician, storage, pharmacy/biologic handling, emergency capability and inspection requirements should be documented before launch.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Regulatory Dossier: Mexico Advertising
Patient-facing claims should be reviewed under Mexican health-advertising rules and U.S. consumer-protection exposure where Americans are targeted.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Regulatory Dossier: U.S. Patient Acquisition
A foreign clinic marketing to U.S. patients should clearly state investigational status and avoid creating the impression of FDA approval. Referral relationships should also be reviewed for fee-splitting and other legal issues.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
IP Dossier: Expansion Process
Claim-level FTO should focus on the actual cytokines, feeder constructs, culture sequence, media, activation, selection and scale-up process contemplated for an owned lab.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
IP Dossier: CAR and Engineering
If the business later moves into engineered NK cells, CAR architecture, gene-editing targets, cytokine armoring and vector technology substantially expand the IP landscape.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
IP Dossier: Methods of Treatment
Treatment patents may claim combinations, dosing sequences, target indications or biomarker-selected populations. Clinic use and manufacturing partnerships should be reviewed against relevant jurisdictions.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Commercial Dossier: Off-the-Shelf Economics
The core economic thesis is manufacturing multiple doses from a donor or master source and carrying cryopreserved inventory. Real economics depend on batch success, release testing, wastage, shipping and treatment volume.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Commercial Dossier: Vertical Integration
An owned lab may improve margin and supply control but creates fixed cost, validation, quality-system, personnel and IP burdens. The decision should be volume-triggered.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Investor Dossier: Evidence Claims Matrix
Every external claim should be tagged as established biology, human clinical evidence, early clinical signal, preclinical rationale, company-reported information or management projection.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Investor Dossier: Red-Flag Claims
Avoid 'cure,' 'proven,' 'FDA-approved NK therapy,' or generalized efficacy claims. Do not cite a CAR-NK trial as direct proof that a different unmodified NK product will work.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.
Investor Dossier: Data Room Requirements
The data room should contain CMO quality documents, product specifications, certificates of analysis, stability data, regulatory opinions, clinic licenses, physician credentials, adverse-event SOPs, insurance, IP review and clinical evidence tables.
Required diligence record
Investor-facing interpretation
The scientifically defensible statement should be no broader than the evidence. Where evidence comes from a different NK source, engineering platform, dose, conditioning regimen, combination therapy or cancer type, the relationship should be described as supportive rationale rather than direct proof.
Decision standard
Advance only after the supporting primary literature and product-specific documents have been reviewed by the relevant scientific, medical, regulatory and legal advisers. Material uncertainty should be disclosed rather than resolved by assumption.